Abstract 2566
Background
Data on functional imaging parameters such as blood volume (BV) in metastatic renal cell carcinoma (mRCC) is limited. We assessed the association of baseline BV with survival outcome adjusted for baseline clinical factor in patients with mRCC.
Methods
BV was quantified using dynamic contrast-enhanced computed tomography in patients from two prospective studies; Angiogenesis Inhibitor Study (AIS) with pazopanib, sunitinib and temsirolimus and the Danish Renal Cancer Group Study-1 (Darenca-1) with interleukin-2, interferon alpha with or without bevacizumab. Data were analyzed using an Advanced Perfusion and Permeability Application softwareprogram, Phillips. BV was evaluated as a binary (above/below median) and as a continuous variable adjusted for treatment, gender, and individual IMDC factors. Association was evaluated using chi squared test for clinical factors, Cox regression for overall survival (OS) and progression-free survival (PFS), and logistic regression for objective response rate (ORR).
Results
Among 122 included patients, 105 patients had technically feasible scans and were included in the final analysis (AIS, N = 29 and Darenca-1, N = 76). Median BV was 32.87 mL * 100 g-1 (range 9.52 to 92.87). BV above median was associated with IMDC favorable risk group (p = 0.004), metastasis free interval > 1 year (p = 0.007) and male gender (p = 0.032). BV below median was associated with anemia (p = 0.040) and neutrophilia (p = 0.007). Patients with high vs. low baseline BV had longer PFS (12.5 vs. 5.6 months, p = 0.015) and longer OS (42.2 vs. 22.4 months, p = 0.001), respectively. In multivariate analysis, high baseline BV remained an independent favorable prognostic factor (OS: HR 0.49, 95% CI 0,30-0,78, p = 0.003, PFS: HR 0.64; 95% CI 0,42-0,97, p = 0.040). BV analyzed as a continuous variable was also associated with OS in multivariate analysis (HR 0.98, 95% CI 0,96-1,00, p = 0,017). No association was found between BV and ORR (OR 1.56; 95% CI 0,67-3,63, p = 0.3).
Conclusions
High baseline BV, obtained using functional imaging, is a new independent favorable prognostic factor associated with longer PFS and OS in patients with mRCC. Further research in functional imaging is encouraged.
Clinical trial identification
NCT01274273 (Darenca-1 Study).
Editorial acknowledgement
Legal entity responsible for the study
Authors.
Funding
Phillips Healthcare provided the software used for DCE-CT analysis Roche and Novartis supported the clinical part of the study financially - but were however not invovled in the imaging analysis.
Disclosure
A. Drljevic-Nielsen: Research grant / Funding (institution), Travel / Accommodation / Expenses: Ipsen; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: BMS. F. Donskov: Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Ipsen. All other authors have declared no conflicts of interest.
Resources from the same session
3047 - Health-related quality of life in Greek haematogical malignancies patients undergoing chemotherapy
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract
1121 - Experiences of endocrine therapy after breast cancer surgery
Presenter: Susanne Ahlstedt Karlsson
Session: Poster Display session 3
Resources:
Abstract
2305 - The effects of progressive muscle relaxation and mindfulness meditation on fatigue, coping styles, and quality of life in breast cancer patients receiving adjuvant paclitaxel regimen: An-assessor blinded, three-arm randomized controlled trial
Presenter: Zehra Gok Metin
Session: Poster Display session 3
Resources:
Abstract
4561 - Agreement between breast cancer patients and oncologists on the severity of patients’ symptoms and functions during a one-year follow-up after treatment.
Presenter: Randi Reidunsdatter
Session: Poster Display session 3
Resources:
Abstract
1768 - Taste Changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Gulcan Bagcivan
Session: Poster Display session 3
Resources:
Abstract
1830 - CART-19: a comparative between literature versus experience
Presenter: Cassandra Andersson Vila
Session: Poster Display session 3
Resources:
Abstract
4027 - Unplanned emergency department use by people receiving ambulatory anti-cancer agents with potential febrile neutropenia
Presenter: Meritxell Casanovas-Blanco
Session: Poster Display session 3
Resources:
Abstract
4754 - Examining the benefits of medical exercise during radiotherapy in patients after mastectomy
Presenter: Nikolina Dodlek
Session: Poster Display session 3
Resources:
Abstract
2510 - Assessment Quality of Life with Hand-Foot Syndrome Induced by Apatinib Combined with Anti-PD-1 Therapy in NSCLC
Presenter: Qi Jiang
Session: Poster Display session 3
Resources:
Abstract
2989 - Adverse effects of chemotherapy influence the patients’ quality of life : Analysis of implicated factors
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract